The effect of COVID vaccination timing on the seroprevalence of IgG antibodies: evidence from the Guayas region of Ecuador
The results suggest that a significant portion of the study population was already infected with SARS-CoV-2 prior to the vaccination. As expected, seropositivity increased alongside vaccination efforts. We determined that Pfizer vaccine recipients should be adhered to vaccine timing guidelines. Furthermore, resource-limited countries should consider administering vaccines with flexibility in dosing intervals, such as AstraZeneca, as it allows for a wider time frame without significantly reducing the boosting of IgG antibodies.
Authors
- Gabriel Morey-León (ORCID: https://orcid.org/0000-0003-1824-8285)
- Derly Andrade-Molina (ORCID: https://orcid.org/0000-0002-2651-5884)
- Fernando Espinoza-Fuentes
- Bernard Moscoso (ORCID: https://orcid.org/0000-0001-5345-4717)
- Juan Carlos Fernández‐Cadena (ORCID: https://orcid.org/0000-0002-0398-8371)
- Lauren A. Rhodes (ORCID: https://orcid.org/0000-0002-6639-5354)
- Gonzalo E. Sánchez (ORCID: https://orcid.org/0000-0003-2523-5407)
- Joséfina Coloma (ORCID: https://orcid.org/0000-0003-0222-6487)
- Ángel Guevara (ORCID: https://orcid.org/0000-0002-5299-6925)
- Aurora Malacatus-Arboleda
- Erick Barbotó-Ramírez
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Central University of Ecuador (EC)
- Escuela Superior Politecnica del Litoral (EC)
- Universidad Espíritu Santo (EC)
- University of California, Berkeley (US)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2025-03-25
- DOI
- https://doi.org/10.3389/fpubh.2025.1537049
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00